Sophia Vourli

Dr. Sophia Vourli

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in Life
Verified
Journal Article
Open access
PDF file
MPMichalis Polemis
Michalis Polemis
GGeorgia Mandilara
Georgia Mandilara
OPOlga D. Pappa
Olga D. Pappa
AAAthina Argyropoulou
Athina Argyropoulou
EPEfstathia Perivolioti
Efstathia Perivolioti
KTKyriaki Tryfinopoulou
Kyriaki Tryfinopoulou
Changes in hospitals’ daily practice due to COVID-19 pandemic may have an impact on antimicrobial resistance (AMR). We aimed to assess this possible impact as captured by the Greek Electronic System for the Surveillance of Antimicrobial Resistance (WHONET-Greece). Routine susceptibility data of 17,837 Gram-negative and Gram-positive bacterial isolates from blood and respiratory specimens of hospitalized patients in nine COVID-19 tertiary hospitals were used in order to identify potential differences in AMR trends in the last three years, divided into two periods, January 2018–March 2020 and April 2020–March 2021. Interrupted time-series analysis was used to evaluate differences in the trends of non-susceptibility before and after the changes due to COVID-19. We found significant differences in the slope of non-susceptibility trends of Acinetobacter baumannii blood and respiratory isolates to amikacin, tigecycline and colistin; of Klebsiella pneumoniae blood and respiratory isolates to meropenem and tigecycline; and of Pseudomonas aeruginosa respiratory isolates to imipenem, meropenem and levofloxacin. Additionally, we found significant differences in the slope of non-susceptibility trends of Staphylococcus aureus isolates to oxacillin and of Enterococcus faecium isolates to glycopeptides. Assessing in this early stage, through surveillance of routine laboratory data, the way a new global threat like COVID-19 could affect an already ongoing pandemic like AMR provides useful information for prompt action.

7 November 2024 in Eurosurveillance
Verified
Journal Article
Open access
Iosif MeletiadisIosif Meletiadis
Iosif Meletiadis
MSMaria Siopi
Maria Siopi
BSBram Spruijtenburg
Bram Spruijtenburg
PGPanagiota-Christina Georgiou
Panagiota-Christina Georgiou
MKMaria Kostoula
Maria Kostoula
Spyros PournarasSpyros Pournaras
Spyros Pournaras
After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread ofCandida auris-related invasive infections has been observed globally. However, the contemporary epidemiology ofC. aurisfungaemias in Greece remains unknown. An outbreak ofC. aurisbloodstream infections has been ongoing for almost 3 years in a Greek tertiary care academic hospital, with 89C. auris-driven episodes appearing in five waves every 6–7 months following peaks in colonisation rates by 3–4 months. All isolates clustered in clade I and were genetically related, 84% were fluconazole-resistant and all were non-resistant to amphotericin B and echinocandins, except one pan-echinocandin-resistant isolate (FKS1S639Fmutant) recovered from a patient on empiric therapy with anidulafungin. Notably,C. auriswas in 2023 the most prevalent (34%) cause of candidaemia in our hospital. The accelerated and long-term transmission dynamics ofC. aurisfungaemia underscore the need for rigorous infection control measures, while antifungal stewardship is warranted to contain the selection of echinocandin-resistant isolates.

27 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
AVAlexandra Vasilakopoulou
Alexandra Vasilakopoulou
PKPolyxeni Karakosta
Polyxeni Karakosta
SVSophia Vourli
Sophia Vourli
EKEleni Kalogeropoulou
Eleni Kalogeropoulou
Spyros PournarasSpyros Pournaras
Spyros Pournaras
We report a preliminary evaluation of the NG-Test CARBA 5 immunochromatographic assay for detecting carbapenemases directly from rectal swabs on the same day of sampling. Thirty fecal swabs were examined for carbapenemase-producing organisms (CPOs) by conventional culture, PCR, and NG-Test CARBA 5. Each sample was tested by the immunochromatographic assay five times, including direct testing and incubation in trypticase soy broth for 1, 2, 3, and 4 h. Twenty patients yielded CPOs by culture. Immunochromatographic and PCR results were concordant and detected the same 25 carbapenemases (11 KPC, 8 VIM, and 6 NDM). In five cases, we detected co-carriage of KPC and VIM. Compared with PCR, the sensitivity of NG-Test CARBA 5 for the detection of KPC, VIM, and NDM was 80% without incubation, 88% with one hour, 92% with two, and 100% with three hours incubation, while specificity was 100% for all time points. All samples containing adequate fecal content were detected by NG-Test CARBA 5 concordantly with PCR, without incubation. NG-Test CARBA 5 is a reliable test that rapidly detects the presence of carbapenemases at the same day of sampling, directly from rectal swabs. It thus provides early information to guide antimicrobial treatment and infection control interventions.

1 June 2015 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SVSophia Vourli
Sophia Vourli
FFF. Frantzeskaki
F. Frantzeskaki
JMJ. Meletiadis
J. Meletiadis
LSL. Stournara
L. Stournara
AAA. Armaganidis
A. Armaganidis
GDG. Dimopoulos
G. Dimopoulos

21 November 2024 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
PKPolyxeni Karakosta
Polyxeni Karakosta
Georgios MeletisGeorgios Meletis
Georgios Meletis
EKElisavet Kousouli
Elisavet Kousouli
EPEfthymia Protonotariou
Efthymia Protonotariou
ATAikaterini Tarpatzi
Aikaterini Tarpatzi
Spyros PournarasSpyros Pournaras
Spyros Pournaras

30 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PPPaschalis Paranos
Paschalis Paranos
SVSophia Vourli
Sophia Vourli
Spyros PournarasSpyros Pournaras
Spyros Pournaras
Iosif MeletiadisIosif Meletiadis
Iosif Meletiadis
In the light of increasing antimicrobial resistance among gram-negative bacteria and the lack of new more potent antimicrobial agents, new strategies have been explored. Old antibiotics, such as colistin, temocillin, fosfomycin, mecillinam, nitrofurantoin, minocycline, and chloramphenicol, have attracted the attention since they often exhibit in vitro activity against multi-drug-resistant (MDR) gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The current review provides a summary of the in vitro activity, pharmacokinetics and PK/PD characteristics of old antibiotics. In silico modelling was then performed using Monte Carlo simulation in order to combine all preclinical data with human pharmacokinetics and determine the probability of target (1-log kill in thigh/lung infection animal models) attainment (PTA) of different dosing regimens. The potential of clinical efficacy of a drug against severe infections by MDR gram-negative bacteria was considered when PTA was >95% at the epidemiological cutoff values of corresponding species. In vitro potent activity against MDR gram-negative pathogens has been shown for colistin, polymyxin B, temocillin (against E. coli and K. pneumoniae), fosfomycin (against E. coli), mecillinam (against E. coli), minocycline (against E. coli, K. pneumoniae, A. baumannii), and chloramphenicol (against E. coli) with ECOFF or MIC90 ≤ 16 mg/L. When preclinical PK/PD targets were combined with human pharmacokinetics, Monte Carlo analysis showed that among the old antibiotics analyzed, there is clinical potential for polymyxin B against E. coli, K. pneumoniae, and A. baumannii; for temocillin against K. pneumoniae and E. coli; for fosfomycin against E. coli and K. pneumoniae; and for mecillinam against E. coli. Clinical studies are needed to verify the potential of those antibiotics to effectively treat infections by multi-drug resistant gram-negative bacteria.